MARKET WIREYahoo Finance • 1d ago
Should Value Investors Buy Innoviva (INVA) Stock?Yahoo Finance report covering Innoviva Inc. (INVA) market action, institutional positioning, and fundamental catalysts.
Why INVA Stock slipped -0.94% Today — RQD Quant Desk Flash
$21.02 -0.94% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $20.94
Innoviva Inc. (INVA) carries a Roarable Rating of C (Hold) with 65/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
ROARABLE C • HOLD / WATCH
Cap $1.53B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on INVA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is INVA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Innoviva Inc. (NASDAQ: INVA) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 65/100 at a spot price of $21.02 (-0.94% 1D, market cap $1.53B). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 14/20, and Executive Insider Alignment 15/20. Across 1015 tracked Health Care issuers, INVA ranks #118 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does INVA compare to OCUL and GPCR in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), INVA carries a Roarable C (65/100 RQD), trailing P/E of N/A, gross margin of 74.8%, and ROIC of 14.7%. By comparison, OCUL (Ocular Therapeutix Inc.) holds a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $1.53B) and GPCR (Structure Therapeutics Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -19.5%, cap $1.56B). Among the 5-stock peer group, PAHC leads on earnings multiple (32.7x) while INVA leads on capital efficiency (14.7% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for INVA?
▼
Per INVA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001080014), Innoviva Inc. generated $411.3M in revenue (+14.7% YoY), $0 in net income, and $195.8M in free cash flow against $1.64B in total assets and $257.7M in total debt. Key quantitative strengths: Strong cash generator (74.8% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $20.94 (-0.36%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 15/20 (B) • 47.6% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 65/100 (C) historically posted market-perform odds over rolling 90-day windows (+1.3% avg 90D alpha vs SPY • 55.6% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERHOLD / WATCH • C
Quant Analyst Panel Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR RQD RADARRw C · Rk C+
Each axis scored 0–20
12M PRICE TARGET CONE+3.1% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for INVA)Realized 20D OHLCV Swing Band: ±4.5%
Deterministic 5-Pillar Attribution (65/100 Composite)
🔍 WHY INVA SCORES 65/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+15/20 pts (23% of score)
SEC XBRL FY 2025 (10-K): 47.6% FCF Margin ($195.8M FCF) & 74.8% Gross Margin
▲ #2 Bullish Driver: Insider Conviction & Share Dilution+15/20 pts (23% of score)
SEC Form 4 / 13F Thermometer: 75% Net Buy • Cannibal Buyback (-2.08% YoY Shares)
▼ #1 Drag / Risk Factor: Whale & Options Positioning8/20 pts (-12 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-12 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C$20.74+2.6% Next Q
57
Q2 (-2Q)Grade C$21.28-1.6% Next Q
60
Q3 (-1Q)Grade C+$20.94+0.4% Next Q
62
CurrentGrade C$21.02+1.3% Hist 90D α
65
Trajectory: C (57) → C (65)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the INVA Bull Thesis Could Fail
Even with a 65/100 (C) score, INVA faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Broader market pullbacks can still drag down strong stocks in the short run.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 72.3% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($21.00) or 200D SMA ($21.90) invalidates the momentum regime and cuts Target Base ($21.68) toward Bear Floor ($16.91).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $INVA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “INVA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why INVA Stock slipped -0.94% Today — RQD Quant Desk Flash
Innoviva Inc. (INVA) slipped -0.94% to $21.02, trading at 44% of its 52-week range ($17.84 – $25.15). Solid 74.8% gross margin (15% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 44% of its 52-week range ($17.84 – $25.15) with RSI-14 at 53.1 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±4.5% around $21.02 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable C (Hold) backed by 74.8% gross margin and $195.8M annual free cash flow.
Live INVA Headlines & Catalysts
MARKET WIREChartMill • 1d ago
Innoviva Inc (NASDAQ:INVA): A Decent Value Stock With an Undervalued Earnings ProfileChartMill report covering Innoviva Inc. (INVA) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESeeking Alpha • 1d ago
Innoviva And Its Real Value (NASDAQ:INVA)Seeking Alpha report covering Innoviva Inc. (INVA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Do Options Traders Know Something About Innoviva Stock We Don't?Yahoo Finance report covering Innoviva Inc. (INVA) market action, institutional positioning, and fundamental catalysts.
CATALYSTSimply Wall St • 1d ago
Does Chlamydia Coinfection Data Change The Bull Case For Innoviva Stock (INVA)?Simply Wall St report covering Innoviva Inc. (INVA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 2d ago
INVA vs. MRK: Which Stock Is the Better Value Option?Yahoo Finance report covering Innoviva Inc. (INVA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.siam.in/ • 2d ago
Innoviva (INVA) Ticks Higher to $21.19 as Royalty-Driven Model Holds Attention - Volatility Smirkhttps://www.siam.in/ report covering Innoviva Inc. (INVA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 2d ago
Is Innoviva (INVA) Undervalued As Zacks Flags Its Value Appeal?Yahoo Finance report covering Innoviva Inc. (INVA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 4d ago
AbbVie (ABBV) Tops Q3 Earnings and Revenue EstimatesAbbVie (ABBV) delivered earnings and revenue surprises of +2.14% and +0.20%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
MARKET WIREYahoo • 5d ago
Eli Lilly (LLY) Surpasses Q3 Earnings and Revenue EstimatesLilly (LLY) delivered earnings and revenue surprises of +39.03% and +10.37%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (INVA Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
INVA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -8.57%📐 HORIZONTAL RANGE
2026-11-03O $21.31H $21.31L $21.02C $21.02VOL 623.3K
RES: $21.64SUP: $20.26SMA50: $21.00SMA200: $21.90
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
INVA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
-2.2%/yr Implied 5Y Growth
vs. +14.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on INVA today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for INVA. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for INVA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (INVA)
Health Care Rank #118 of 1015
⚔️ OCUL vs INVA Full Matrix →
1. Head-to-Head Health Care Peer Comparison (INVA vs. OCUL, GPCR, ETON, PAHC)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Innoviva Inc. (INVA) ranks #118 by composite RQD confidence (65/100, grade C) and #299 by equity capitalization ($1.53B). Within this direct 5-issuer industry benchmark cohort, PAHC leads on earnings valuation at 32.7x trailing P/E, while INVA leads on capital efficiency and profitability with 14.7% ROIC and 74.8% gross margin. INVA currently leads its immediate peer cohort in composite quantitative strength at 65/100 (C).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| INVA
ACTIVE
Innoviva Inc. | C | 65/100 | — | 74.8% | 14.7% | -0.94% | $1.53B | Benchmark Subject |
| OCUL Ocular Therapeutix Inc. | E | 24/100 | — | 87.3% | -35.0% | -3.44% | $1.53B | /ocul-vs-inva → |
| GPCR Structure Therapeutics Inc. | E | 27/100 | — | — | -19.5% | -6.40% | $1.56B | /gpcr-vs-inva → |
| ETON Eton Pharmaceuticals Inc. | D+ | 57/100 | — | 53.5% | -0.9% | -2.63% | $1.49B | /eton-vs-inva → |
| PAHC Phibro Animal Health Corporation (Class A) | D+ | 56/100 | 32.7x | 30.9% | 9.9% | -0.36% | $1.58B | /pahc-vs-inva → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001080014 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Innoviva Inc. (INVA) reported GAAP revenue of $411.3M (+14.7% vs. FY2024 revenue of $358.7M , and +32.5% cumulative change since FY2023) , GAAP net income of $0, operating cash flow of $196.9M, and free cash flow of $195.8M (+3.9% YoY). On the balance sheet, INVA closed FY2025 with $1.64B in total assets against $257.7M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $411.3M | $0 | $196.9M | $195.8M | $1.64B | $257.7M |
| FY2024 (FY) | 2024-12-31 | $358.7M | $0 | $188.7M | $188.4M | $1.30B | $256.3M |
| FY2023 (FY) | 2023-12-31 | $310.5M | $0 | $141.1M | $141.1M | — | — |
3. INVA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs INVA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Innoviva Inc. (NASDAQ: INVA) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 65/100 at a spot price of $21.02 (-0.94% 1D, market cap $1.53B). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 14/20, and Executive Insider Alignment 15/20. Across 1015 tracked Health Care issuers, INVA ranks #118 in composite RQD confidence.
How does INVA compare to OCUL and GPCR in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), INVA carries a Roarable C (65/100 RQD), trailing P/E of N/A, gross margin of 74.8%, and ROIC of 14.7%. By comparison, OCUL (Ocular Therapeutix Inc.) holds a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $1.53B) and GPCR (Structure Therapeutics Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -19.5%, cap $1.56B). Among the 5-stock peer group, PAHC leads on earnings multiple (32.7x) while INVA leads on capital efficiency (14.7% ROIC).
What are the biggest fundamental strengths and SEC risk factors for INVA?
Per INVA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001080014), Innoviva Inc. generated $411.3M in revenue (+14.7% YoY), $0 in net income, and $195.8M in free cash flow against $1.64B in total assets and $257.7M in total debt. Key quantitative strengths: Strong cash generator (74.8% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.
Where is INVA trading relative to its 50-day, 200-day, and 52-week technical levels?
INVA last traded at $21.02 (-0.94% on volume of 1,120,585 shares), positioning the stock +0.10% above its 50-day simple moving average ($21.00) and -4.02% below its 200-day simple moving average ($21.90). Across its 52-week range of $17.84 to $25.15, INVA sits at the 43.5% percentile with a 14-day RSI of 53.1 (NEUTRAL RANGE) and an implied next-earnings move of ±4.5% ($20.07 to $21.97).
ROARABLE RATING BRIEF • RQD 65/100 (C)
✓ SEC XBRL & RQD VERIFIED
INVA — Innoviva Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Innoviva Inc. (INVA) earns a live Roarable RQD composite score of 65/100, corresponding to a C letter grade (Roarable Hold) at a spot price of $21.02 (-0.94% 1D, market capitalization $1.53B).
- Fundamental Cash Engine (15/20): Anchored by return on invested capital (ROIC) of 14.7%, gross margin of 74.8%, operating margin of 39.8%, and free cash flow yield of 12.72%.
- Whale 13F & Options Flow (8/20) + Insider Conviction (15/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (14/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 6/9, and Debt/Equity of 0.22x.
2. Business Model, Unit Margins & SEC Financial Trajectory
Innoviva Inc. (INVA) is a NASDAQ-listed issuer classified in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry..5B. — describes the company's specific products, customers, or revenue model beyond the sector and industry classification.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Innoviva Inc. (INVA) reported $411.3M in annual revenue (up from $358.7M in FY2024, +14.7% YoY) and $0 in GAAP net income. Over the multi-year SEC filing window from FY2023 ($310.5M revenue, $0 net income) through FY2025, INVA scaled operating cash flow to $196.9M and free cash flow to $195.8M, backed by $1.64B in total assets against $257.7M in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (C • RQD 65/100): Strong cash generator (74.8% gross margin)—profits are backed by real money, not accounting tricks. Company leadership has skin in the game with net positive insider conviction. With Fundamental Cash Engine at 15/20 and Institutional Whale Flow at 8/20, sustained execution supports upside toward the upper end of the $17.84 – $25.15 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh current valuation and 7.6x EV/EBITDA against 39.8% operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Operating in Biotechnology: Pharmaceutical Preparations (Health Care), INVA carries a macro regime beta of 1.00 and gross margin of 74.8%.
- Key Question #1: Can INVA sustain or expand its 39.8% operating margin and 14.7% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $411.3M and free cash flow of $195.8M, how will capital allocation balance growth reinvestment against $257.7M in total debt?
- Key Question #3: How sensitive is INVA's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
INVA Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Innoviva Inc. (INVA) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 1d ago
Should Value Investors Buy Innoviva (INVA) Stock? Yahoo Finance report covering Innoviva Inc. (INVA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE ChartMill • 1d ago
Innoviva Inc (NASDAQ:INVA): A Decent Value Stock With an Undervalued Earnings Profile ChartMill report covering Innoviva Inc. (INVA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Seeking Alpha • 1d ago
Innoviva And Its Real Value (NASDAQ:INVA) Seeking Alpha report covering Innoviva Inc. (INVA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Do Options Traders Know Something About Innoviva Stock We Don't? Yahoo Finance report covering Innoviva Inc. (INVA) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Simply Wall St • 1d ago
Does Chlamydia Coinfection Data Change The Bull Case For Innoviva Stock (INVA)? Simply Wall St report covering Innoviva Inc. (INVA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 2d ago
INVA vs. MRK: Which Stock Is the Better Value Option? Yahoo Finance report covering Innoviva Inc. (INVA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.siam.in/ • 2d ago
Innoviva (INVA) Ticks Higher to $21.19 as Royalty-Driven Model Holds Attention - Volatility Smirk https://www.siam.in/ report covering Innoviva Inc. (INVA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 2d ago
Is Innoviva (INVA) Undervalued As Zacks Flags Its Value Appeal? Yahoo Finance report covering Innoviva Inc. (INVA) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
INVA Bull vs. Bear Conversation Board — What's Your Call at $21.02?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON INVA 🐻 33% BEARISH CONVICTION
AL AlphaFlow_Cap RQD DEBATE OPENER • Verified $100K Arena Trader 🐂 BULLISH
🎯 Target: $27.80 (+31.0%)
📌 Pinned Debate Strong cash generation, with FY 2025 FCF of $195.8M and a 12.72% FCF yield, supports the fundamental pillar.
Don't sleep on INVA's setup in Health Care. Strong cash generation, with FY 2025 FCF of $195.8M and a 12.72% FCF yield, supports the fundamental pillar.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (65/100) backs up the fundamental quality.
RetailWhale_TX 🐂 BULL
Both sides have a point here — INVA's 13/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH
🎯 Target: $18.04 (-15.0%)
Spot @ $21.22 Reported net income of $0.0M across all periods and missing EPS/P/E data leave earnings quality unverifiable.
Sitting on the sidelines or leaning short INVA above $21.22. Reported net income of $0.0M across all periods and missing EPS/P/E data leave earnings quality unverifiable.. Until Fundamental Cash Engine (15/20) and FCF yield (12.72%) inflect higher, upside is capped near $25.15.